ReviewBMC neurology2026
Autoimmune glial fibrillary acidic protein astrocytopathy with full-length spinal cord lesions: a case report and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAutoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is an autoimmune inflammatory disease of the central nervous system triggered by GFAP. Currently, the diagnosis is mainly based on the detection of autoantibodies that recognize GFAP in the cerebrospinal fluid. Its imaging manifestations are complex and variable. It is extremely necessary to enhance the understanding of this disease among radiologists and reduce the damage caused by invasive procedures. CASE PRESENTATION: We report a case of a 39-year-old female patient with lesions throughout the spinal cord. The patient presented with recurrent fever without obvious cause, and no obvious lesions were found in the lung CT examination. Two months later, she developed weakness of both lower limbs with neck and back pain. Contrast-enhanced MRI of the cervical and thoracic spinal cord demonstrated diffuse intramedullary punctate-to-linear and patchy enhancement, with associated leptomeningeal enhancement. GFAP-IgG was subsequently detected in the cerebrospinal fluid, confirming the diagnosis of GFAP-A. After intravenous methylprednisolone pulse therapy combined with immunoglobulin therapy, the lesion extent of the patient was significantly reduced.
conclusionsThe MRI manifestations of GFAP-A patients are complex. When there is a whole spinal cord lesion, acute infectious lesions should be considered, but GFAP-A should also be kept in mind. In cases where CSF antibody test results are negative or weakly positive, a diagnosis of GFAP-A can still be established when characteristic imaging manifestations are consistent with clinical symptoms. Follow-up observation by MRI examination is necessary to avoid recurrence when the dose of steroid hormones is reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.